7JN Stock Overview
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Poolbeg Pharma PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.10 |
| 52 Week High | UK£0.12 |
| 52 Week Low | UK£0.065 |
| Beta | 2.26 |
| 1 Month Change | 0% |
| 3 Month Change | 6.60% |
| 1 Year Change | 51.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 13.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7JN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.7% | 0.4% | -1.2% |
| 1Y | 51.1% | -29.0% | 1.2% |
Return vs Industry: 7JN exceeded the German Pharmaceuticals industry which returned -29% over the past year.
Return vs Market: 7JN exceeded the German Market which returned 1.2% over the past year.
Price Volatility
| 7JN volatility | |
|---|---|
| 7JN Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7JN has not had significant price volatility in the past 3 months.
Volatility Over Time: 7JN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 12 | Jeremy Skillington | www.poolbegpharma.com |
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
Poolbeg Pharma PLC Fundamentals Summary
| 7JN fundamental statistics | |
|---|---|
| Market cap | €57.32m |
| Earnings (TTM) | -€5.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.0x
P/E RatioIs 7JN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7JN income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£4.89m |
| Earnings | -UK£4.89m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0098 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7JN perform over the long term?
See historical performance and comparison